Valuation : Personalis, Inc.

Market Cap 1.84B 1.58B 1.49B 1.36B 2.54B 173B 2.55B 17.57B 6.82B 88.99B 6.9B 6.75B 287B P/E 2026 *
-15.7x
P/E 2027 * -18.3x
Enterprise Value 1.66B 1.43B 1.34B 1.23B 2.3B 157B 2.3B 15.87B 6.16B 80.38B 6.23B 6.1B 259B EV / Sales 2026 *
20.1x
EV / Sales 2027 * 15.8x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day+2.20%
1 week+0.76%
Current month+2.50%
1 month+27.22%
3 months+60.00%
6 months+100.93%
Current year+116.08%
1 week 16.44
Extreme 16.44
17.38
1 month 13.13
Extreme 13.13
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
Chief Executive Officer 65 31/12/2022
President 55 13/03/2026
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/7/26 Exercice

Chairperson

300,000 0.2865%
9/7/26 Exercice

Chief Executive Officer

300,000 0.2865%
29/6/26 Exercice

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%+0.76%+228.24%+961.73% 1.84B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.61%+0.56%+91.18%+204.31% 27.68B
Weighted average by Cap. -1.01%+0.11%+90.40%+133.84%

Financials

2026 *2027 *
Net sales 82.47M 70.96M 66.77M 60.99M 114M 7.79B 114M 789M 306M 3.99B 310M 303M 12.87B 110M 94.83M 89.22M 81.5M 152M 10.4B 153M 1.05B 409M 5.34B 414M 405M 17.2B
Net income -115M -99.04M -93.18M -85.12M -159M -10.87B -160M -1.1B -427M -5.58B -432M -423M -17.96B -102M -87.73M -82.54M -75.4M -141M -9.63B -141M -975M -378M -4.94B -383M -374M -15.91B
Net Debt -178M -153M -144M -131M -246M -16.77B -246M -1.7B -659M -8.6B -667M -652M -27.72B -91.04M -78.34M -73.71M -67.33M -126M -8.6B -126M -871M -338M -4.41B -342M -334M -14.21B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
04/09/26 USD 17.20 +2.20% 2,522,867
03/09/26 USD 16.83 +0.60% 2,494,050
02/09/26 USD 16.73 -1.93% 2,227,164
01/09/26 USD 17.06 +1.67% 3,619,033
31/08/26 USD 16.78 -1.70% 2,845,863
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
17.20USD
Average target price
15.44USD
Spread / Average Target
-10.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock